Crick — Clinical Intelligence Platform

Early research (Phase 1)Study completedNCT01209143

What this trial is testing

Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists

Who this might be right for

Solid Cancers

Genentech, Inc. 52

Results for “Solid Tumor Refractory to Standard Therapy”

A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine

Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients

Safety, Tolerability, PK, Anti-Tumor Activity of STP705 in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy

GDC-0449 in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists

First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors

A Phase I Study of LXP1788 Injection with Advanced Solid Tumors.

Single-dose Escalation Study of SQ-001 Infusion to Characterize the PK Profiles of Major Sentinel Compounds in Healthy Adult Volunteers in US

AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors

A Dose Escalation, Dose Expansion Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-575, in Subjects With Advanced Tumors.

Phenoxodiol in Treating Patients With Refractory Solid Tumors

Phase 1 Study With Sorafenib and Sirolimus

NKTR-102 in Combination With Cetuximab in Patients With Refractory Solid Tumors (Phase 2a) and Metastatic or Locally Advanced Colorectal Cancer (Phase 2b)

Anti-VEGF Monoclonal Antibody hPV19 in Patients With Solid Tumors

Safety and Efficacy Study of Epitope Peptide To Treat HLA-A24 or A02-positive Advanced Solid Tumors

Phase 1 Safety and Tolerability Study of Andes-1537 for Injection in Patients With Advanced Unresectable Solid Tumors

Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors

L19TNFα in Patients With Advanced Solid Tumors

Bortezomib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors

Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain

Results for “Solid Tumor Refractory to Standard Therapy”

A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine

Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients

Safety, Tolerability, PK, Anti-Tumor Activity of STP705 in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy

GDC-0449 in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists

First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors

A Phase I Study of LXP1788 Injection with Advanced Solid Tumors.

Single-dose Escalation Study of SQ-001 Infusion to Characterize the PK Profiles of Major Sentinel Compounds in Healthy Adult Volunteers in US

AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors

A Dose Escalation, Dose Expansion Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-575, in Subjects With Advanced Tumors.

Phenoxodiol in Treating Patients With Refractory Solid Tumors

Phase 1 Study With Sorafenib and Sirolimus

NKTR-102 in Combination With Cetuximab in Patients With Refractory Solid Tumors (Phase 2a) and Metastatic or Locally Advanced Colorectal Cancer (Phase 2b)

Anti-VEGF Monoclonal Antibody hPV19 in Patients With Solid Tumors

Safety and Efficacy Study of Epitope Peptide To Treat HLA-A*24 or A*02-positive Advanced Solid Tumors

Phase 1 Safety and Tolerability Study of Andes-1537 for Injection in Patients With Advanced Unresectable Solid Tumors

Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors

L19TNFα in Patients With Advanced Solid Tumors

Bortezomib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors

Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain

Safety and Efficacy Study of Epitope Peptide To Treat HLA-A24 or A02-positive Advanced Solid Tumors